DIA

Ventyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. » Mehr auf zacks.com

Today, we look at Ventyx Biosciences, Inc., a clinical-stage biopharma company focused on developing small molecule products for inflammatory diseases. The company has now had two major trial disappointments in the span of a month, triggering a huge selloff in the shares. However, the company's pipeline still has a few "shots on goal" and the stock is now trading below net cash on the balance sheet. » Mehr auf seekingalpha.com

Ventyx Biosciences (NASDAQ: VTYX ) stock is falling hard on Tuesday after the clinical-stage biopharmaceutical company released poor study results. These results come from a Phase 2 clinical trial of VTX958 in patients suffering from moderate to severe plaque psoriasis. » Mehr auf investorplace.com